

TURKEY

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<ul style="list-style-type: none"> There haven't been any changes in pricing of medicines since October 2014. <u>Change in communique of pricing:</u> Some changes in "<i>Communique on Pricing of Human Drugs</i>" are planned by Turkish Medicines and Medical Devices Agency (TMMDA) but it's time is uncertain. Biggest changes in communique which are expected include decreasing price reviews frequency to once in 6 months, increasing price of medicines easier which threat public health when they are absent in the market. 	<ul style="list-style-type: none"> <u>Introducing alternative reimbursement models:</u> In September 2014, a new law was enacted which gives Social Security Institution (SSI) to improve alternative reimbursement models and to make risk sharing agreements with pharmaceutical companies. However, The Directive for these models hasn't been introduced yet. <u>Changes in reimbursement list:</u> In July 2014, 150 new medicines were added to the list to reimburse. In September 2014, some changes have been implemented in the <i>Communique of Health Practice</i>. New medicines were added to the list to reimburse.
	Other changes 2014	
S P E C I A L T O P I C	High cost medicines	
	<ul style="list-style-type: none"> <u>Special pricing policies:</u> There are no specific pricing policies for high cost medicines. <u>Special reimbursement/funding policies:</u> SSI is now working on alternative reimbursement models especially with new high-priced medicines. But before carrying out these agreements, a Directive has to be introduced to give more details. <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> High cost medicines are reimbursed regardless of the out-patient or in-patient sector. <u>Key challenges:</u> New high cost medicines and their budget impact <u>Solutions:</u> Starting risk-sharing agreements and analysing clinical outcomes and sales of these medicines every year. 	